Sarepta FDA Hearing, page-57

Once ANP successfully completes Phase 3, it significantly mitigates investment risk and becomes an attractive prospect for larger pharmaceutical companies. These companies are willing to acquire a company for hundreds of millions or even billions of dollars, as long as it aligns with their investment policies.

I believe ANP still has a chance to reach that stage. However, it is crucial for the management to be meticulous in meeting the requirements of regulatory bodies such as the FDA, EMA, Australian TGA, and others.

Considering the plight of boys suffering from DMD, if this medication can improve their quality of life, there is a compelling reason to swiftly bring it to the market.